"10.1371_journal.pone.0137106","plos one","2015-09-01T00:00:00Z","Atsuko Nakayama; Hiroyuki Morita; Tomoko Nakao; Toshihiro Yamaguchi; Tomokazu Sumida; Yuichi Ikeda; Hidetoshi Kumagai; Yoshihiro Motozawa; Tsukasa Takahashi; Atsushi Imaizumi; Tadashi Hashimoto; Ryozo Nagai; Issei Komuro","Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Department of Translational Research for Healthcare and Clinical Science, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Theravalues Corporation, Tokyo, Japan","Conceived and designed the experiments: AN HM AI TH RN. Performed the experiments: AN HM TN TY TT. Analyzed the data: AN HM YI HK YM. Contributed reagents/materials/analysis tools: TS AI TH RN IK. Wrote the paper: HM IK.","The corresponding author has read the journal's policy and the authors of this manuscript have the following competing interests: This research is supported by Theravalues Corporation (Tokyo, Japan). Tsukasa Takahashi, Atsushi Imaizumi and Tadashi Hashimoto are employed by Theravalues Corporation. In the future, they might participate in the exploitation of a kind of luteolin compound. A. Nakayama, H. Morita, T. Hashimoto, and R. Nagai are named on a patent (Heart failure suppressing agent US 20140194372 A1) for the usefulness of a luteolin compound. There are no further patents, products in development or marketed products to declare. This does not alter the authorsâ€™ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2015","09","Atsuko Nakayama","AN",13,TRUE,5,5,5,2,TRUE,TRUE,FALSE,0,NA,FALSE
